Search research articles
Contact Us
Filters
Showing results (1-10 of 25) with videos related to
Page
of 3
Sort By:
Cell Chemical Biology
|
February 16, 2024
Cellular reprogramming by protein degradation: The next frontier in cancer immunotherapy
Erik Ehinger, Anjana Rao
The Journal of Headache and Pain
|
April 18, 2026
Trigeminal neuralgia is associated with increased risk of cerebrovascular disease, myocardial infarction and suicide - a nationwide Swedish study
Erik Ehinger, Erik Kronvall, Erik Uvelius
Cancers
|
June 12, 2026
Has Glioblastoma Five- and Ten-Year Survival Been Affected by New Treatment Algorithms in Population-Based Data? A Retrospective Swedish Survey Between 1958 and 2015
Peter Milos, Erik Ehinger, Edward Visse, et al.
Current Opinion in Lipidology
|
July 19, 2018
Atherosclerosis in the single-cell era
Holger Winkels, Erik Ehinger, Yanal Ghosheh, et al.
BMC Neurology
|
February 21, 2023
Antisecretory factor is safe to use as add-on treatment in newly diagnosed glioblastoma
Erik Ehinger, Jan Kopecky, Anna Darabi, et al.
Circulation Research
|
March 18, 2017
Endothelial Protective Monocyte Patrolling in Large Arteries Intensified by Western Diet and Atherosclerosis
Amado Quintar, Sara McArdle, Dennis Wolf, et al.
International Journal of Cardiology
|
November 23, 2015
Prognostic impact of macrophage migration inhibitory factor in patients with non-ischemic heart failure undergoing endomyocardial biopsy
Karin A L Mueller, Johannes Schwille, Saskia Vollmer, et al.
Biorxiv : the Preprint Server for Biology
|
February 12, 2026
Reversible control of T cell exhaustion by NR4A transcription factors revealed through targeted protein degradation
Erik Ehinger, Kristy C Perez, Emi Sanchez, et al.
Nature Communications
|
July 25, 2017
Natural variation of macrophage activation as disease-relevant phenotype predictive of inflammation and cancer survival
Konrad Buscher, Erik Ehinger, Pritha Gupta, et al.
Trials
|
March 14, 2025
Antisecretory factor as add-on treatment for newly diagnosed glioblastoma, IDH wildtype: study protocol for a randomized double-blind placebo-controlled trial
Erik Ehinger, Anna Darabi, Edward Visse, et al.
Page
of 3
Search research articles
Search
Showing results (1-10 of 25) with videos related to
Sort By:
Page
of 3
Cell Chemical Biology
|
February 16, 2024
Cellular reprogramming by protein degradation: The next frontier in cancer immunotherapy
Erik Ehinger, Anjana Rao
The Journal of Headache and Pain
|
April 18, 2026
Trigeminal neuralgia is associated with increased risk of cerebrovascular disease, myocardial infarction and suicide - a nationwide Swedish study
Erik Ehinger, Erik Kronvall, Erik Uvelius
Cancers
|
June 12, 2026
Has Glioblastoma Five- and Ten-Year Survival Been Affected by New Treatment Algorithms in Population-Based Data? A Retrospective Swedish Survey Between 1958 and 2015
Peter Milos, Erik Ehinger, Edward Visse, et al.
Current Opinion in Lipidology
|
July 19, 2018
Atherosclerosis in the single-cell era
Holger Winkels, Erik Ehinger, Yanal Ghosheh, et al.
BMC Neurology
|
February 21, 2023
Antisecretory factor is safe to use as add-on treatment in newly diagnosed glioblastoma
Erik Ehinger, Jan Kopecky, Anna Darabi, et al.
Circulation Research
|
March 18, 2017
Endothelial Protective Monocyte Patrolling in Large Arteries Intensified by Western Diet and Atherosclerosis
Amado Quintar, Sara McArdle, Dennis Wolf, et al.
International Journal of Cardiology
|
November 23, 2015
Prognostic impact of macrophage migration inhibitory factor in patients with non-ischemic heart failure undergoing endomyocardial biopsy
Karin A L Mueller, Johannes Schwille, Saskia Vollmer, et al.
Biorxiv : the Preprint Server for Biology
|
February 12, 2026
Reversible control of T cell exhaustion by NR4A transcription factors revealed through targeted protein degradation
Erik Ehinger, Kristy C Perez, Emi Sanchez, et al.
Nature Communications
|
July 25, 2017
Natural variation of macrophage activation as disease-relevant phenotype predictive of inflammation and cancer survival
Konrad Buscher, Erik Ehinger, Pritha Gupta, et al.
Trials
|
March 14, 2025
Antisecretory factor as add-on treatment for newly diagnosed glioblastoma, IDH wildtype: study protocol for a randomized double-blind placebo-controlled trial
Erik Ehinger, Anna Darabi, Edward Visse, et al.
Page
of 3